--- title: "What's Behind The Rise In Artelo Biosciences Stock?" type: "News" locale: "en" url: "https://longbridge.com/en/news/283382950.md" description: "Artelo Biosciences, Inc. (NASDAQ:ARTL) shares rose 8.56% to $4.82 after the publication of a peer-reviewed article on FABP5 as a therapeutic target for pain. This announcement comes amid a broader market decline, with the S&P 500 down 0.4%. Despite the recent gains, ARTL is still below key moving averages, indicating a longer-term downtrend. The stock has a 12-month return of -73.31%, with key support at $5.00 and resistance at $6.00, as traders monitor its ability to maintain momentum." datetime: "2026-04-20T16:06:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283382950.md) - [en](https://longbridge.com/en/news/283382950.md) - [zh-HK](https://longbridge.com/zh-HK/news/283382950.md) --- # What's Behind The Rise In Artelo Biosciences Stock? **Artelo Biosciences, Inc. ( ARTL )** shares jumped on Monday after the company announced the publication of a peer‑reviewed article highlighting FABP5 as a therapeutic target for pain. The move is drawing extra attention as broader markets edged lower, with the S&P 500 down 0.4% and Healthcare slipping 0.30%. - Artelo Biosciences ( ARTL ) stock is showing exceptional strength. What’s fueling ARTL momentum? ## Artelo Highlights Peer-Reviewed Article On Pain Treatment Artelo Biosciences ( ARTL ) announced that a peer‑reviewed article focused on FABP5 as a therapeutic target for pain was published, putting a spotlight on its science and pipeline narrative. The update hit as Healthcare is currently a bottom-performing sector on the day, ranking 9 out of 11 sectors. “This peer-reviewed publication strengthens the scientific foundation for ART26.12 and reinforces our view that FABP5 inhibition represents a novel mechanism of action with the potential to redefine the treatment of pain,” said **Andrew Yates**, Artelo’s chief scientific officer. ## ARTL Shares Trade Below Key Averages Artelo is still working to repair a longer-term downtrend, with the stock sitting far below its 200-day simple moving average (SMA), which often acts like a "line in the sand" for long-term trend followers. At $5.12, the stock is trading 24% below its 20-day SMA and 1.2% below its 100-day SMA, which leans bearish for short-term momentum while showing it's trying to stabilize in the intermediate term. The moving average convergence divergence (MACD), a trend/momentum measure, remains bearish with the MACD line below the signal line, which typically aligns with sellers having the edge on follow-through. With support near $5.00 and resistance near $6.00, traders are watching whether the breakout attempt can hold above support rather than fading back into the prior range. The 12-month return is -73.31%, which underscores how much downside the stock has absorbed over the past year. Even after recent swings, the stock remains much closer to its $2.96 52-week low than its $85.80 high, a setup that often keeps rallies choppy unless new catalysts keep arriving. - **Key Resistance**: $6.00 — an area where rebounds have recently struggled to push through. - **Key Support**: $5.00 — a level buyers have defended, and a key "hold" zone for the current move. ## ARTL Shares Rise On Monday **ARTL Stock Price Activity:** Artelo Biosciences ( ARTL ) shares were up 8.56% at $4.82 at the time of publication on Monday, according to Benzinga Pro data. _Image: Shutterstock_ ### Related Stocks - [ARTL.US](https://longbridge.com/en/quote/ARTL.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md) - [SSTK.US](https://longbridge.com/en/quote/SSTK.US.md) ## Related News & Research - [Artelo Biosciences Q1 net loss widens, R&D expenses fall](https://longbridge.com/en/news/286462732.md) - [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md) - [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)